Chat technology for personalized drug development and discovery via conversation
CompanyInsilico Medicine, Pak Shek Kok, Hong Kong SAR of China
Insilico Medicine specializes in optimizing the development of new drugs and personalized therapeutic approaches. The AI-based platform PandaOmics combines machine learning with genetic data analysis. To identify and evaluate potential drug candidates, the AI uses a huge data set. The OMICS database includes all relevant biochemical information on genomics, epigenomics, transcriptomics and proteomics. In addition, the AI takes connections from publications, grants, patents and clinical studies into account. The company develops specific deep learning algorithms to simulate diseases and analyse patient-specific data. Disease modelling enables targeted drug target analysis, the development of (personalized) drugs and the identification of disease-specific biomarkers. The platform automatically saves the newly gained insights in the database to be taken into account in future analyses. Insilico Medicine's latest innovation is the integration of a new language program: ChatPandaGPT. This allows researchers to converse with the AI in natural language and navigate their studies verbally in a simple and straightforward manner. In summary, the PandaOmics platform proves to be a valuable method that can help accelerate personalized drug discovery and improve risk management.
Panda Omics
info@insilicomedicine.com
Added on: 11-29-2023
[1] https://www.bionity.com/en/news/1179832/insilico-medicine-brings-ai-powered-chatpandagpt-to-its-target-discovery-platform.html[2] https://insilico.com/pandaomics
